Key result
Treatment with the beta-blocker ICI 66.082 alone achieved satisfactory blood pressure control in 15 of 25 male patients with mild to moderate hypertension.
Why the study?
Does ICI 66.082 improve blood pressure control in mildly to moderately hypertensive males?
Does ICI 66.082 improve blood pressure control in mildly to moderately hypertensive males?
The new beta-blocker ICI 66.082 provided satisfactory blood pressure control in the majority of mildly to moderately hypertensive males without impairing work capacity or ventilatory function.
Answers are grounded in this paper and cite their sources.
May support beta-blocker monotherapy in mild-moderate hypertensive males; leaves open randomized confirmation and broader applicability.
From a survey of 1250 males, 40-60 years of age, 25 mildly to moderately hypertensive patients have been offered treatment with the new beta-blocker ICI 66.082. Before and during the trial, data were obtained on resting BP and pulse rate, BP, pulse rate and ECGs during near maximal exercise, and various ventilatory function tests. In 15 patients, satisfactory BP control was obtained with ICI 66.082 alone, 25-100 mg twice daily. In 5 patients, the addition of hydralazine or a diuretic was necessary for satisfactory response. In 2 patients satisfactory control was not achieved and 3 patients were excluded for various reasons. Although BP and maximal pulse rate fell markedly during exercise, the total work capacity was not significantly reduced. No deleterious effect on ventilatory function was noted.
No takes yet. Share an insight, caveat, or question.
Erikssen et al. (1975) studied Hypertension (n=25). ICI 66.082 was evaluated on Satisfactory BP control. Treatment with the beta-blocker ICI 66.082 alone achieved satisfactory blood pressure control in 15 of 25 male patients with mild to moderate hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: